Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 14, 2021Open Access

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant

View Full Paper
Ask AI
Bookmark
Share

Authors

PHPaul T. HeathUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro”EGEva GalizaSt George's, University of LondonDBD. N. BaxterNational Health Service

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Heath et al. (2021) studied this question.

synapsesocial.com/papers/6ab4a793c00cd19ff64d3ceehttps://doi.org/10.1101/2021.05.13.21256639
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373 in Younger and Older Adults2021 · 24 citations
  2. 2Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant2021 · 42 citations
  3. 3Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine2020 · 1,247 citations
  4. 4Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study2021 · 871 citations
  5. 5SARS-CoV-2 Variants of Concern in the United States—Challenges and Opportunities2021 · 380 citations